Tag archive for ‘PLX’
Zami Aberman Pluristem

Pluristem’s Study Results Showing Improved Bone Marrow Transplantation

Pluristem Therapeutics Inc.(Nasdaq:PSTI; DAX: PJT: PLTR;TASE:PSTI), a developer of placenta-based cell therapy products, announced today strong positive data from a preclinical study of PLX-R18 cells to More...

Gali Weinreb On Wednesday, October 15th, 2014

Ebola anxiety boosts Protalix again

– Smallcap investor network report: An experimental Ebola drug can be produced on Protalix‘s vegetable platform. Anxiety about the Ebola disease increased again at the end of last week, when More...

Shiri Habib-Valdhorn On Thursday, August 21st, 2014

Israeli biomedical Protalix loses half value in 1 year

– The Israeli biomedical company now faces competition for both of its drugs. – The share price of Protalix Biotherapeutics Inc. (NYSE MKT:PLX; TASE: PLX) plunged 7.6% yesterday to its lowest point More...

Pluristem Signs Korean Licensing Deal : Includes $10 million Share Swap

– – The Israeli stem cell company, Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) has signed a strategic partnership and exclusive licensing agreement with South Korea’s Cha Bio&Diostech More...

Wordpress site Developed by Fixing WordPress Problems